Sign in Subscribe
Endocrinology

Estrogen's Impact on Transcervical Tight Junctional Resistance

Strategic Insights

— 1 min read

Researchers from the United States have made a breakthrough discovery regarding the hormone estrogen's effects on the human cervix. The study, led by R. Zeng and colleagues from the University Hospitals of Cleveland, found that estrogen reduces transcervical tight junctional resistance by accelerating the modulation of the tight junction-specific protein occludin. This modulation occurs through post-translational up-regulation of occludin turnover, which leads to the generation of a unique 50-kDa occludin isoform.

Key Takeaways:

  • Estrogen significantly reduces transcervical tight junctional resistance in a time- and dose-related manner.
  • The hormone has no significant effect on the expression of E-Cadherin, zonula-occluden-1, or Claudin-4.
  • Estrogen modulates the expression of the transmembrane tight-junctional protein occluding, particularly at low concentrations (1 and 10 nM).
  • The RTJ and occludin effects of estrogen are reversible and can be blocked by tamoxifen but not progesterone.
  • The effects of estrogen on occludin expression are distinct from those of proteinase-K, plasmin, and matrix-metalloproteinase-2.
  • The study suggests that the occludin 50-kDa form is an estrogen-specific-induced occludin isoform.

Statistics:

  • 1 and 10 nM concentrations of 17beta-estradiol increased the density of occludin 65-kDa form.
  • 100 nM concentration of 17beta-estradiol induced a mild 2-fold increase in the density of occludin 65-kDa form.
  • Estrogen increased the expression of occludin 50-kDa form in a dose-related manner.
  • The study was published in the Journal of Clinical Endocrinology and Metabolism (Volume 89, Issue 10, 2004).

Sources:

  • R. Zeng and colleagues, University Hospitals of Cleveland, Journal of Clinical Endocrinology and Metabolism (Estrogen abrogates transcervical tight junctional resistance by acceleration of occludin modulation. J Clin Endocrinol Metab, 2004;89(10):5145-5155).
  • G.I. Gorodeski, University Hospitals of Cleveland, contact email: [ggorodeski @mediacl.wolrd.org](mailto:ggorodeski@mediacl.wolrd.org).

Read more